Mineral metabolism in CKD: adaptation devolves into maladaptation.

Slides:



Advertisements
Similar presentations
Ca++, PO4, PTH & VIT D Calcium, Phosphorus & Vitamin D
Advertisements

Bone Disease in Renal Failure Dr Anne Kleinitz and Dr Cherelle Fitzclarence
Uncontrolled secondary hyperparathyroidism in a haemodialysis patient Jordi Bover, MD, PhD Fundació Puigvert Barcelona, Spain © Springer Healthcare, a.
Calcium & phosphor disturbance CKD- MBD Dr. Atapour.
Hyperparathyroidism in Chronic Kidney Disease 醫五 李政霆.
Calcium metabolism & parathyroid glands
Secondary Hyperparathyroidism in Chronic Kidney Disease 2009/11/13 신장내과 R3 이완수.
Pharmacology of drugs used in calcium & vitamin D disorders
What is the Bone?. Connective tissue  Organic matrix (cells & proteins)  Inorganic elements (calcium hydroxyapatite)
PTH Calcitonin 10mg% Vitamin D Lecture 52 Ca++ Homeostasis
Renal Osteodystrophy ( paraclinical evaluation ) Dr. Y. Ataipour Hashemi Nejad Hospital TUMS.
Daniel Bikle, John Adams, and Sylvia Christakos
Agents that Affect Bone Mineral Homeostasis Agents that Affect Bone Mineral Homeostasis By Dr. Sasan Zaeri (PharmD, PhD) (PharmD, PhD) Department of Pharmacology.
Calcium, Phosphorus, Magnesium and Related Disorders (By Basil OM Saleh) Objective: 1. Calcium & Phosphorus homeostasis, Hypercalcaemia, and Hypocalcaemia.
A simplified schema for the regulation of serum phosphate by PTH, 1,25(OH)2D and fibroblast growth factor 23 (FGF23). FGF23 is produced predominantly by.
Volume 79, Pages S3-S8 (April 2011)
Bone and Mineral Metabolism and Fibroblast Growth Factor 23 Leves After Kidney Donation Gustavo Fernandes Ferreira, Giselle Guerra, Eva Schiavenato, Fabina.
Modification of the trade-off hypothesis of Slatopolsky and Bricker as it relates to the adaptation of the body to decreased functional renal mass in an.
Bone Metabolism MSS/Biochemistry, fall-2017
Chapter 21: Regulation of Calcium and Magnesium
Effects of active metabolites of vitamin D (D), parathyroid hormone (PTH), calcitonin (CT), and fibroblast growth factor 23 (FGF23) on calcium and phosphorus.
Vitamin D is a group of fat-soluble secosteroids responsible for intestinal absorption of calcium and phosphate. It is not actually an essential dietary.
Figure 1 Disruption of phosphate homeostasis in chronic kidney disease (CKD) Figure 1 | Disruption of phosphate homeostasis in chronic kidney disease (CKD).
Volume 67, Pages S1-S7 (June 2005)
High Prevalence of Vitamin D Inadequacy and Implications for Health
CKD–Mineral and Bone Disorder: Core Curriculum 2011
Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.
Agents That Affect Bone Mineral Homeostasis
Volume 73, Issue 1, Pages 3-5 (January 2008)
The Gutsy Side of Bone Cell Metabolism
Fibroblast Growth Factor 23 and CKD Prognosis
Measure Baseline 1 year p Coronary calcium scores
Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.
High Prevalence of Vitamin D Inadequacy and Implications for Health
CKD–Mineral and Bone Disorder: Core Curriculum 2011
Phosphorus: Another Devil in Our Diet?
FGF23 or PTH: which comes first in CKD ?
Pieter Evenepoel, Myles Wolf  Kidney International 
Figure 4 Model of changes in the serum levels
Tilman B. Drüeke, Ziad A. Massy  Kidney International 
Volume 64, Issue 6, Pages (December 2003)
FGF23–parathyroid interaction: implications in chronic kidney disease
Volume 79, Pages S24-S27 (April 2011)
Volume 79, Pages S3-S8 (April 2011)
M. Fukagawa, S. Nakanishi, J.J. Kazama  Kidney International 
Tally Naveh-Many, Justin Silver  Kidney International 
Volume 79, Pages S20-S23 (April 2011)
Use of vitamin D in chronic kidney disease patients
Clinical relevance of FGF-23 in chronic kidney disease
Volume 69, Issue 3, Pages (February 2006)
Osteoblasts Osteocytes Osteoclasts Cells of Bone Osteoblasts Osteocytes Osteoclasts.
Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.
Volume 87, Issue 3, Pages (March 2015)
Fibroblast growth factor 23: the making of a hormone
Phosphate and the parathyroid
Latest findings in phosphate homeostasis
Volume 71, Issue 8, Pages (April 2007)
Volume 78, Issue 10, Pages (November 2010)
Conceptual model of the course of chronic kidney disease (CKD).
The ins and outs of phosphate homeostasis
Diagram of the mechanisms involved in limiting the ability of the kidney to maintain the levels of 1,25-dihydroxyvitamin D in chronic kidney disease (CKD).
Patient factors that increase risk for drug-induced nephrotoxicity.
Marta Christov, Harald Jüppner  Kidney International 
Tamara Isakova, Orlando M. Gutiérrez, Myles Wolf  Kidney International 
Association between hyperphosphatemia (serum phosphorus ≥4
Causal diagrams that represent three possible relationships between smoking, ESRD, and albumin-to-creatinine ratio (ACR) in the Study of Heart and Renal.
Attributable risk for disorders of mineral metabolism.
Parathyroid hormone (PTH) -fibroblast growth factor 23 (FGF23) feedback loop. Parathyroid hormone (PTH) -fibroblast growth factor 23 (FGF23) feedback loop.
Untangling Klotho's Role in Calcium Homeostasis
Regulation of serum calcium homeostasis.
Presentation transcript:

Mineral metabolism in CKD: adaptation devolves into maladaptation. Mineral metabolism in CKD: adaptation devolves into maladaptation. (A) Adaptation: High dietary phosphate intake and reduced phosphate excretory capacity due to CKD stimulate bone production of fibroblast growth factor-23 (FGF-23). Increased FGF-23 levels stimulate phosphaturia and reduce circulating concentrations of 1,25-dihydroxyvitamin D, which decreases the efficiency of intestinal calcium and phosphate absorption. Secondary increases in parathyroid hormone levels in response to impaired calcium absorption further enhance phosphaturia and stimulate bone resorption. Collectively, these adaptations result in normal serum calcium and phosphate levels. (B) Maladaptation: Continuous activation of these initially adaptive pathways due to unrelenting CKD may lead ultimately to maladaptive adverse effects in several end organs, including cardiac hypertrophy that promotes heart failure, progression of CKD to ESRD, and renal osteodystrophy that increases risk of fracture. Myles Wolf CJASN 2015;10:1875-1885 ©2015 by American Society of Nephrology